Sign In
Buy R
$260.38
+2.32 (+0.90%)
At Close: Jun 03, 2026
CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes
12:30pm, Thursday, 13'th Feb 2025
This Press Release updates numerical list in reference section Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of
Ryder Included in Forbes' Canada's Best Employers List for 2025
06:55am, Thursday, 13'th Feb 2025
MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) celebrates the recognition by Forbes as one of Canada's Best Employers in 2025. As a top supply chain and transportation company in the logistics b
Theralase(R) Demonstrates Effective Treatment of Herpes
04:15pm, Wednesday, 12'th Feb 2025
Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ACCE
Ryder System, Inc. (R) Q4 2024 Earnings Call Transcript
02:19pm, Wednesday, 12'th Feb 2025
Ryder System, Inc. (NYSE:R ) Q4 2024 Earnings Conference Call February 12, 2025 11:00 AM ET Company Participants Calene Candela - Vice President, Investor Relations Robert Sanchez - Chairman and Chief
Ryder (R) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
11:01am, Wednesday, 12'th Feb 2025
Although the revenue and EPS for Ryder (R) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street es
Caldwell and Bennett Jones Announce the 2024 Recipient of Canada's Outstanding CEO of the Year(R)
09:30am, Wednesday, 12'th Feb 2025
TORONTO, ON / ACCESS Newswire / February 12, 2025 / Caldwell (TSX:CWL)(OTCQX:CWLPF) and Bennett Jones today announced Canada's Outstanding CEO of the Year® for 2024 is WSP Global's Alexandre L'Heureu
Ryder (R) Tops Q4 Earnings Estimates
09:06am, Wednesday, 12'th Feb 2025
Ryder (R) came out with quarterly earnings of $3.45 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $2.95 per share a year ago.
Ryder Reports Fourth Quarter 2024 Results and Provides 2025 Outlook
06:55am, Wednesday, 12'th Feb 2025
MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) reported results for the three months ended December 31 as follows: (In millions, except EPS) Earnings Before Taxes Earnings Diluted Earni
R's Q4 Earnings Coming Up: What's in the Offing for the Stock?
10:05am, Tuesday, 11'th Feb 2025
R's fourth-quarter 2024 revenues are expected to have benefited from strength across all segments.
EdgeTI Recognized in the 2024 Gartner(R) Emerging Tech: Revenue Opportunity Projection of Simulation Digital Twins
03:01am, Tuesday, 11'th Feb 2025
Arlington, Virginia--(Newsfile Corp. - February 11, 2025) - Edge Total Intelligence Inc. (TSXV: CTRL) (OTCQB: UNFYF) (FSE: Q5i) ("edgeTI", "Company"), a leading provider of real-time digital twin soft
Countdown to Ryder (R) Q4 Earnings: Wall Street Forecasts for Key Metrics
10:21am, Monday, 10'th Feb 2025
Besides Wall Street's top -and-bottom-line estimates for Ryder (R), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter
Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses
07:00am, Monday, 10'th Feb 2025
University of Manitoba independent research verifies that RuvidarTM is more effective than acyclovir in the inactivation of Herpes Simplex Viruses post infection. TORONTO, ON / ACCESS Newswire / Febru
Ryder Declares Quarterly Cash Dividend
04:30pm, Friday, 07'th Feb 2025
MIAMI--(BUSINESS WIRE)--The Board of Directors of Ryder System, Inc. (NYSE: R) declared a regular quarterly cash dividend of $0.81 per share of common stock to be paid on March 21, 2025, to shareholde
Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months. 78% of subjects maintained a cli
Zomedica Launches the TRUFORMA(R) Enhanced Endogenous ACTH Assay to aid in Equine PPID Diagnosis
06:30am, Thursday, 06'th Feb 2025
Zomedica continues to redefine what is possible in point of care diagnostics with the TRUFORMA biosensor platform ANN ARBOR, MI / ACCESS Newswire / February 6, 2025 / Zomedica Corp. (NYSE American:ZOM
